Also found in: Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.


 (splē′nō-mĕg′ə-lē, splĕn′ō-)
n. pl. sple·no·meg·a·lies
Enlargement of the spleen.


(Pathology) pathol abnormal enlargement of the spleen
[C20: from Greek splēno-, from splēn spleen + megalo-, from megas large + -y3]


(ˌspli noʊˈmɛg ə li, ˌsplɛn oʊ-)

enlargement of the spleen.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.splenomegaly - an abnormal enlargement of the spleen
hypertrophy - abnormal enlargement of a body part or organ
References in periodicals archive ?
The INREBIC development program consisted of multiple studies (including JAKARTA and JAKARTA2) in 608 patients who received more than one dose (ranging from 30 mg to 800 mg),1 of whom 459 had myelofibrosis,1 including 97 previously treated with ruxolitinib.1 The JAKARTA study evaluated the efficacy and safety of once-daily oral doses of INREBIC compared with placebo in patients with intermediate-2 or high-risk, primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis who were previously untreated with a JAK inhibitor, had enlarged spleens (a condition known as splenomegaly), and had a platelet count of 50 x 109/L (median baseline platelet count was 214 x 109/L; 16%
Felty's syndrome (FS), characterized by the triad of seropositive rheumatoid arthritis (RA), neutropenia and splenomegaly was first described in 1924 [1, 2].
With regards to haemoglobin, the highest mean levels were seen with cases having lymphadenopathy, and the lowest in cases with splenomegaly. The difference in mean Hb levels by one-way ANOVA, resulted in a p value of 0.52.
JAKARTA is a pivotal phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy of daily oral doses (400 mg or 500 mg) of fedratinib compared with placebo in patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis with splenomegaly.
Biopharmaceutical company PharmaEssentia reported on Thursday the receipt of approval from the European Commission (EC) for Besremi (ropeginterferon alfa-2b, P1101) as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly in the European market.
Clinically, the disease is presented with ichthyosis, hearing loss, hepatomegaly, splenomegaly, cirrhosis, cataract, myopathy, and mental retardation.
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder predominantly of adult life, having a male preponderance.1 These patients have variable presentations.2 Some are completely asymptomatic, their disease being diagnosed incidentally on routine blood CP while others may have symptoms due to anemia or splenomegaly.3 CML is usually diagnosed on peripheral blood film but the detection of the BCR-ABL fusion transcript by molecular techniques is necessary for establishing a definitive diagnosis.4
A retrospective review of the patient's history revealed that he had a small decrease in blood cell number (particularly neutrophils) and splenomegaly during fevers when he was treated in neurological department at the beginning.
In 2014, panel physicians from the International Organization for Migration (IOM), who conduct Department of State-required predeparture examinations for U.S.-bound refugees at resettlement sites in Uganda, noticed an unusually high number of Congolese refugees with enlarged spleens, or splenomegaly. Many conditions can cause splenomegaly, such as various infections, liver disease, and cancer.
Extra pulmonary signs and symptoms seen in some forms of atypical CAP may include Mental confusion, Myalgias, Ear pain, Abdominal pain, Diarrhea, Rash, Nonexudative pharyngitis, Splenomegaly and Relative bradycardia.